Office of Technology Transfer – University of Michigan

Antibody for Acute and Chronic Inflammatory Diseases

Technology #3810

Background

Toll like receptors (TLRs) are a family of conserved pathogen recognition receptors that are integral to innate immune responses. Among the 13 TLR members in mammal, TLR3 recognizes viral PAMPs. The role of TLR3 in viral-induced pathology has been extensively studied in the context of gene deficient mice. TLR3 activation following viral infection appears to elicit two major responses: effective immunity and/or bystander tissue injury. The latter aspect of TLR3 activation has been shown as TLR3 deficient mice show various responses to viral infections including decreased mortality and/or disease upon infection with influenza A, West Nile virus, and Phlebovirus. Thus, TLR3 could be a novel potential therapeutic target during inflammatory events.

Technology

This invention details the novel potential in targeting TLR3 during acute and chronic inflammatory events in several organs including those present within the respiratory, gastrointestinal, cardiovascular, and renal systems. Researchers at the University of Michigan have observed that the expression and activation of TLR3 contribute to tissue injury and dysfunction in a number of murine models of clinically relevant diseases. The researchers have also invented a novel antibody that specifically detects TLR3 on immune (i.e. macrophages) and non-immune (i.e. fibroblasts) cells in both mouse and human, and, more importantly, this antibody blocks the activity of TLR3 in the in vivo models of tissue injury and disease.

Applications and Advantages

Applications

  • Novel therapeutic strategy for acute and chronic inflammatory diseases
  • Novel drug for treating acute and chronic inflammatory diseases

Advantages

  • The first discovery of TLR3 as a therapeutic target for acute and chronic inflammatory diseases in various organs and provides a novel therapeutic agent.